Zealand Pharma Loses Fifth of Value After Trial Dropouts
Danish biotech Zealand Pharma saw its stock slide after disclosing a 20% dropout rate in its weight-loss drug trial d...
Shifts in income, goals, or family needs make change necessary; use this guide to justify and implement thoughtful budget updates.
26,233 articlesDanish biotech Zealand Pharma saw its stock slide after disclosing a 20% dropout rate in its weight-loss drug trial d...
A new AI-driven outlook on XRP is stirring market chatter as XRP hovers around $1.14. Analysts weigh whether the pred...
Broadcom faced a sharp earnings-driven selloff, tumbling about 14% in a single day. This article spotlights an under-...
Artificial intelligence is delivering measurable efficiency in health care, but the race now focuses on who benefits—...
In 2026, XMAG has surged while MAGS has slipped, underscoring a shift from mega-cap AI bets to broad-market exposure....
Medicare costs hinge on MAGI two years prior, making Roth withdrawals a strategic lever for retirees. New data show m...
Bitcoin steadies near key levels as geopolitical headlines and a high-profile IPO test appetite for risk. Regulators ...
Investors are debating whether removing the weakest members of the S&P 500 improves long-term results. Here's what th...
A working widow filed for survivor benefits at 61 and saw monthly checks shrink as the Social Security earnings test ...
AI-led gains cool as a quintet of warning signs reappear, drawing parallels to the late-2000s Nasdaq run. Investors b...
Early data from U.S. host cities show a modest but tangible lift in tourism and employment during the tournament wind...
Enbridge approaches its 52-week high as cash flow strengthens and a robust project backlog fuels optimism. Analysts c...